Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP)(the “Company” or “Havn Life”), is pleased to announce Its financial results for the three month period ended July 31, 2020. Please note that all references to currency are in CDN dollars. First Quarter Results for three months ended July 31, 2020 – Financial highlights: …
Havn Life Sciences Inc. Reports Q1 Financial Statements Read More »
Havn Retail, a core pillar of Havn Life continues to reach milestones as the company works towards its launch of a line of retail products Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP)(the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive …
Havn Life Sciences submits range of natural health products to Health Canada Read More »
Havn Life is now cross-listed and trades on both the CSE & FSE Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP)(the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce that it …
Havn Life Sciences announces listing approval on the Frankfurt Stock Exchange Read More »
Havn Life will develop methods for safe, standardized, quality- controlled production of medical compounds extracted from the Psilocybe spp. mushroom September 10, 2020 Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants …
Havn Life Sciences granted Section 56 exemption to begin scientific work with psilocybin Read More »
Havn Life Sciences will trade on the CSE under the Ticker Symbol HAVN September 8, 2020 Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce that …
Psychedelics company Havn Life announces commencement of public trading on the CSE Read More »
September 4, 2020 Vancouver, BC – Havn Life Sciences Inc. (the “Company” or “Havn Life”), is pleased to announce that it has successfully completed its acquisition of HAVN Research Inc. (“HAVN Research”), acquiring 100% of the outstanding shares of HAVN Research (the “Acquisition Transaction”). HAVN Research is a biotechnology company engaged in the business of the …
Havn Life Sciences Announces Completion of Acquisition Transaction Read More »
Gary Leong has over 30 years’ experience in the Pharmaceutical and Natural Health Products Industry. July 6, 2020 Vancouver, BC – Havn Life Sciences Inc. (the “Company” or “Havn Life”), announces the appointment of Gary Leong as Chief Science Officer of Havn Life. Mr. Leong has over thirty (30) years of experience in the …
Havn Life Sciences Inc. Announces Appointment of Gary Leong as Chief Science Officer Read More »
Havn Life Sciences Inc. is focused on the standardized, quality-controlled extraction of psychoactive compounds including psilocybin from plants and fungi, and the development of natural health care products from novel compounds. June 25, 2020 Vancouver, BC – Havn Life Sciences Inc. (the “Company” or “Havn Life”), announces launch and filing of its preliminary prospectus. Havn …
Havn Life Sciences Inc. Announces Launch & Filing of Preliminary Prospectus Read More »
